PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 301–400 of 1,009
NK cell exhaustion in the tumor microenvironment
Hao, J., Yang, H., Xiong, H., & Luo, K. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303605 · Cited by 160
Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01846-x · Cited by 129
Self-citationFunctional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Gibbons Johnson, R. M., & Dong, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00961 · Cited by 129
“Hypoxia-inducible factor-1α caused a rapid, dramatic, and selective upregulation of PD-L1 on splenic myeloid-derived suppressor cells (MDSCs) along with macrophages, dendritic cells, and tumor cells (95).”
BackgroundQiu, W., Guo, X., Li, B., Wang, J., Qi, Y., Chen, Z., Zhao, R., Deng, L., Qian, M., Wang, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.023 · Cited by 126
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
Weber, R., Riester, Z., Hüser, L., Sticht, C., Siebenmorgen, A., Groth, C., Hu, X., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000949 · Cited by 139
Wei, F., Wang, D., Wei, J., Tang, N., Tang, L. M., Xiong, F., Guo, C. J., Zhou, M., Li, X., Li, G., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03581-0 · Cited by 148
Vetsika, E.-K., Koukos, A., & Kotsakis, A. (2019) · Cells · doi:10.3390/cells8121647 · Cited by 125
“The main pathway through which they are developed is the Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway, with the members of the STAT protein family being the main downstream signal transductors activating transcription factors such as nuclear factor kappa-light-chain-enhancer of ac…”
BackgroundInfluentialWang, S., Li, J., Xie, J., Liu, F., Duan, Y., Wu, Y., Huang, S., He, X., Wang, Z., & Wu, X. (2018) · Oncogene · doi:10.1038/s41388-018-0252-x · Cited by 135
Yang, J., Ren, B., Yin, X., Xiang, L., Hua, Y., Huang, X., Wang, H., Mao, Z., Chen, W., & Deng, J. (2024) · Advanced Materials · doi:10.1002/adma.202402720 · Cited by 151
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
Wang, Y., Sun, Q., Mu, N., Sun, X., Wang, Y., Fan, S., Su, L., & Liu, X. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00612-y · Cited by 124
Hypoxia-inducible factors in cancer stem cells and inflammation
Peng, G., & Liu, Y. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.003 · Cited by 123
“HIF-1α, but not HIF-2α, upregulates the expression of B7H1/PD-L1 by binding to the HRE of the PD-L1 proximal promoter to enhance expression of PD-L1 [90].”
Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Harding, J. J., El Dika, I., & Abou‐Alfa, G. K. (2016) · Cancer · doi:10.1002/cncr.29769 · Cited by 124
“L1 expression is protean, increasing with modalities that induce hypoxia (ie, embolization or sorafenib).(111,114)”
BackgroundMethodYu, M., Duan, X., Cai, Y., Zhang, F., Jiang, S., Han, S., Shen, J., & Shuai, X. (2019) · Advanced Science · doi:10.1002/advs.201900037 · Cited by 129
Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment
Zhu, S., Wang, Y., Tang, J., & Cao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074477 · Cited by 155
Inflammation as target in cancer therapy
Marelli, G., Sica, A., Vannucci, L. E., & Allavena, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.007 · Cited by 133
Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy
Wegiel, B., Vuerich, M., Daneshmandi, S., & Seth, P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00284 · Cited by 133
Siska, P. J., Singer, K., Evert, K., Renner, K., & Kreutz, M. (2020) · Immunological Reviews · doi:10.1111/imr.12846 · Cited by 123
Immune checkpoint dysfunction in large and medium vessel vasculitis
Watanabe, R., Zhang, H., Berry, G. J., Goronzy, J. J., & Weyand, C. M. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00024.2017 · Cited by 131
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01795-9 · Cited by 120
“[130] reported that HIF-1α, but not HIF-2α, increased the expression of membrane-bound programmed death receptor ligand 1 (PD-L1), an immune checkpoint receptor, which mediates the”
BackgroundTengesdal, I. W., Dinarello, A., Powers, N. E., Burchill, M. A., Joosten, L. A. B., Marchetti, C., & Dinarello, C. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661323 · Cited by 138
Rethinking immune checkpoint blockade: ‘Beyond the T cell’
Liu, X., Hogg, G. D., & DeNardo, D. G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001460 · Cited by 130
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Boreel, D. F., Span, P. N., Heskamp, S., Adema, G. J., & Bussink, J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3913 · Cited by 126
“Furthermore, HIF1a has been identified as a direct regulator of PD-L1, suggesting that combining hypoxia targeting with PD-L1 blockade may improve treatment outcome (37).”
BackgroundLequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117
Self-citationZhu, B., Tang, L., Chen, S., Yin, C., Peng, S., Li, X., Liu, T., Liu, W., Han, C., Stawski, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0314-0 · Cited by 117
“Besides the reported transcription factors IRF1(31), HIF-1(32), STAT1/3(31) and NF-κB(33),”
BackgroundGemcitabine nanoparticles promote antitumor immunity against melanoma
Zhang, Y., Bush, X., Yan, B., & Chen, J. A. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.022 · Cited by 117
Evaluating CAR‐T Cell Therapy in a Hypoxic 3D Tumor Model
Ando, Y., Siegler, E. L., Ta, H. P., Cinay, G. E., Zhou, H., Gorrell, K. A., Au, H., Jarvis, B. M., Wang, P., & Shen, K. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900001 · Cited by 118
Association between pH regulation of the tumor microenvironment and immunological state
Hosonuma, M., & Yoshimura, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1175563 · Cited by 141
Abdul‐Rahman, T., Ghosh, S., Badar, S. M., Nazir, A., Bamigbade, G. B., Aji, N., Roy, P., kachani, H., Garg, N. K., Lawal, L., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01711-z · Cited by 149
Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea
Cubillos-Zapata, C., Avendaño-Ortiz, J., Hernandez-Jimenez, E., Toledano, V., Casas-Martin, J., Varela-Serrano, A., Torres, M., Almendros, I., Casitas, R., Fernández-Navarro, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00833-2017 · Cited by 116
Chang, Y., Yang, C., Lin, M., Wu, C., & Yang, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.012 · Cited by 126
Quetglas, J. I., Labiano, S., Aznar, M. Á., Bolaños, E., Azpilikueta, A., Rodriguez, I., Casales, E., Sánchez-Paulete, A. R., Segura, V., Smerdou, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0216 · Cited by 115
Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia
Phung, C. D., Tran, T. H., Pham, L. M., Nguyen, H. T., Jeong, J., Yong, C. S., & Kim, J. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.029 · Cited by 115
The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy
Lo, A. K., Dawson, W. O., Lung, H. L., Wong, K., & Young, L. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640207 · Cited by 130
Glucose metabolism of TAMs in tumor chemoresistance and metastasis
Liu, J., & Cao, X. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.03.008 · Cited by 129
Brooks, J. M., de Menezes, A. N., Ibrahim, M., Archer, L., Lal, N., Bagnall, C. J., von Zeidler, S. V., Valentine, H. R., Spruce, R. J., Batis, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3314 · Cited by 125
“myeloid-derived suppressor cells (MDSCs) and tumorassociated macrophages (TAMs), may be modulated by tumor hypoxia, which favors suppression (8, 11, 13).”
BackgroundHuang, W., Ran, R., Shao, B., & Li, H. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05371-0 · Cited by 120
Xiang, J., Zhang, N., Sun, H., Su, L., Zhang, C., Xu, H., Feng, J., Wang, M., Chen, J., Liu, L., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.10.025 · Cited by 113
Role of Tumor-Associated Myeloid Cells in Breast Cancer
Cha, Y. J., & Koo, J. S. (2020) · Cells · doi:10.3390/cells9081785 · Cited by 125
“Moreover, MDSC activation induces the expression of PD-L1 and immune suppression [44].”
BackgroundCross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
Shurin, M. R., & Umansky, V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159473 · Cited by 113
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
BackgroundInfluentialPlasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance
Furumaya, C., Martínez-Sanz, P., Bouti, P., Kuijpers, T. W., & Matlung, H. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02100 · Cited by 126
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 124
Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
Park, J. H., & Lee, H. K. (2022) · Cancers · doi:10.3390/cancers14051176 · Cited by 137
Metabolic Interdependency of Th2 Cell-Mediated Type 2 Immunity and the Tumor Microenvironment
Schreiber, S., Hammers, C. M., Kaasch, A. J., Schraven, B. L., Dudeck, A., & Kahlfuß, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632581 · Cited by 126
“This likely occurs as Tregs also use fatty acid oxidation and might even use lactate as fuel (115–117).”
BackgroundInfluentialLan, J., Li, R., Yin, L., Deng, L., Gui, J., Chen, B.-Q., Zhou, L., Meng, M., Huang, Q., Mo, X., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.071 · Cited by 119
“Since MDSCs is a source of PD-L1 (27), the expression of which facilitates the immune suppressive capacity of MDSCs, next we examined total PD-L1 protein in primary tumors, and observed an increase in PD-L1 expression after both radiotherapies (Supplement 2B), but the increase after AHFRT was much lower than that afte…”
Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity
Terry, S., Buart, S., & Chouaïb, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01625 · Cited by 117
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Consonni, F. M., Porta, C., Marino, A., Pandolfo, C., Mola, S., Bleve, A., & Sica, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00949 · Cited by 116
“TGFβ induces the ectoenzymes CD39 and CD73 via HIF-1 α and PGE2 promotes expression of immunosuppressive molecules (IDO1, IL-10, ARG1 and VEGF) as well as repression of immunogenic-associated genes via DNMT3A.”
BackgroundInfluentialRegulation of PD-L1 expression in cancer and clinical implications in immunotherapy.
Ju, X., Zhang, H., Zhou, Z., & Wang, Q. (2020) · PubMed · Cited by 133
Wang, Z., Li, M. Y., Zhang, Z. H., Zuo, H. X., Wang, J. Y., Xing, Y., Ri, M., Jin, H. L., Jin, C. H., Xu, G. H., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104727 · Cited by 115
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Bartee, M. Y., Dunlap, K. M., & Bartee, E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1638 · Cited by 115
“Previous work had indicated that PD1 can also inhibit T cell function by engaging with either PDL2 or PDL1 expressed on a variety of non-tumor cells, such as Tregs (36), myeloid derived suppressor cells (37), or dermal mast cells (38).”
BackgroundCancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 115
“First, hypoxia-inducible factor 1-α (HIF1-α)-mediated tumor-associated hypoxia increases PD-L1 expression on the surface of tumor-infiltrating MDSCs, thus resulting in the inhibition of T cell activity by binding to PD-1 expressed on T cells [21].”
BackgroundMyeloid-Derived Suppressor Cells in Colorectal Cancer
Siemińska, I., & Baran, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01526 · Cited by 125
“Currently, four monoclonal antibodies are already approved by the FDA for the inhibition of this pathway: anti-PD-1 nivolumab and pembrolizumab, and anti-PD-L1 atezolizumab and avelumab.”
BackgroundInfluentialKurt, F. G. Ö., Lasser, S., Arkhypov, I., Utikal, J. S., & Umansky, V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170762 · Cited by 122
“It has been demonstrated that MDSCs express a high level of PD-L1, which interacts with PD-1 on T cells, inducing their anergy (37).”
The emerging roles of macrophages in cancer metastasis and response to chemotherapy
Sanchez, L. R., Borriello, L., Entenberg, D. R., Condeelis, J. S., Oktay, M. H., & Karagiannis, G. S. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0218-056rr · Cited by 114
Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells
Hajizadeh, F., Okoye, I., Esmaily, M., Chaleshtari, M. G., Masjedi, A., Azizi, G., Irandoust, M., Ghalamfarsa, G., & Jadidi‐Niaragh, F. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116952 · Cited by 112
Cao, X., Geng, Q., Fan, D., Wang, Q., Wang, X., Zhang, M., Zhao, L., Jiao, Y., Deng, T., Liu, H., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01704-8 · Cited by 122
“HIF-1α enhances programmed death-ligand 1 (PD-L1) expression on myeloid-derived suppressor cells (MDSCs), macrophages, and tumour cells, impairing T-cell activation [72].”
BackgroundTargeting myeloid-derived suppressor cells for cancer immunotherapy
Liu, Y., Wei, G., Cheng, W. A., Dong, Z., Sun, H., Lee, V. Y., Cha, S.-C., Smith, D. L., Kwak, L. W., & Qin, H. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2175-3 · Cited by 102
“Hypoxia HIF-1α n/a PD-L1 induction [51]”
BackgroundLi, M., Wang, L., Cong, L., Wong, C. C., Zhang, X., Chen, H., Zeng, T., Li, B., Jia, X., Huo, J., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000591 · Cited by 107
“In agreement with this, PD-L1 has been shown to be expressed on MDSCs [35] and TAMs [36] in tumors.”
ResultDi Tacchio, M., Macas, J., Weissenberger, J., Sommer, K., Bähr, O., Steinbach, J. P., Senft, C., Seifert, V., Glas, M., Herrlinger, U., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0865 · Cited by 104
“PD-L1 was upregulated upon aflibercept/AMG386 treatment, which leads to increased hypoxia, a known driver of PD-L1 expression (47).”
BackgroundHypoxia in Solid Tumors: How Low Oxygenation Impacts the “Six Rs” of Radiotherapy
Rakotomalala, A., Escande, A., Furlan, A., Meignan, S., & Lartigau, E. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.742215 · Cited by 128
Guipaud, O., Jaillet, C., Clément-Colmou, K., François, A., Supiot, S., & Milliat, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170762 · Cited by 121
Monoclonal Antibodies: Past, Present and Future
Posner, J., Barrington, P. J., Brier, T., & Datta‐Mannan, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_323 · Cited by 130
Guislain, A., Gadiot, J., Kaiser, A., Jordanova, E. S., Broeks, A., Sanders, J., van Boven, H., de Gruijl, T. D., Haanen, J. B. A. G., Bex, A., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1735-z · Cited by 113
Qorraj, M., Bruns, H., Böttcher, M., Weigand, L., Saul, D., Mackensen, A., Jitschin, R., & Mougiakakos, D. (2016) · Leukemia · doi:10.1038/leu.2016.214 · Cited by 112
Liu, K., Zhang, X., Xu, W., Chen, J., Yu, J. Q., Gamble, J. R., & McCaughan, G. W. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2017.28 · Cited by 112
“The polarization of these TAMs favor a tumor-promoting M2-like phenotype over a tumor-suppressive M1-like phenotype.81 This concept that hypoxia converts the tumor microenvironment from immunosupportive to immunosuppressive appears to also apply in HCC.83 Indeed, both the presence and balance (CD8+ effector cells vs.…”
BackgroundInfluentialTumor microenvironment-responsive manganese-based nanomaterials for cancer treatment
Fan, H., & Guo, Z. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215027 · Cited by 107
MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulation
Liu, L., Wang, Y., Bai, R., Yang, K., & Tian, Z. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.35 · Cited by 114
The network of immunosuppressive pathways in glioblastoma
Mangani, D., Weller, M., & Roth, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.011 · Cited by 111
Mpekris, F., Panagi, M., Voutouri, C., Martin, J. D., Samuel, R., Takahashi, S., Gotohda, N., Suzuki, T., Papageorgis, P., Demetriou, P., et al. (2021) · Advanced Science · doi:10.1002/advs.202001917 · Cited by 102
Several immune escape patterns in non-Hodgkin's lymphomas
Laurent, C., Charmpi, K., Gravelle, P., Tosolini, M., Franchet, C., Ysebaert, L., Brousset, P., Bidaut, A., Ycart, B., & Fournié, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026530 · Cited by 112
Tomić, S., Joksimović, B., Bekić, M., Vasiljević, M., Milanović, M., Čolić, M. J., & Vučević, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00475 · Cited by 114
“Different mechanisms were described to contribute their capacity to induce Treg, including the involvement of CD80, TGF-β (24), PD1L (25), IDO-1 (26), ILT-3 (27), and ILT-4 (7, 28).”
BackgroundRegulation of PD-L1 expression on cancer cells with ROS-modulating drugs
Bailly, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117403 · Cited by 110
Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy
Ma, Z., Wang, L. Z., Cheng, J.-T., Lam, S. T., Ma, X., Xiang, X., Wong, A. L., Goh, B. C., Gong, Q., Sethi, G., et al. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7935 · Cited by 107
“It has been proposed that hypoxia increases tumor cell resistance to immunotherapy by inducing HIF-1 a –dependent programmed cell death ligand 1 (PD-L1) expression in tumor cells and facilitating suppression of T cell activation via monocytic myeloid-derived suppressor cells (3, 65).”
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 106
“The hypoxia-inducible element (HRE), where HIF-1α binds, was found in the PD-L1 proximal promoter [277].”
BackgroundCrosstalk between angiogenesis and immune regulation in the tumor microenvironment
Kim, H. J., Ji, Y. R., & Lee, Y. M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01389-z · Cited by 115
Combination locoregional and systemic therapies in hepatocellular carcinoma
Zhong, B., Fan, W., Guan, J. J., Peng, Z., Jia, Z., Jin, H., Jin, Z.-C., Chen, J.-J., Zhu, H., & Teng, G. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00247-4 · Cited by 121
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
Wang, H.-C., Chan, L.-P., & Cho, S.-F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01084 · Cited by 99
“Afatinib (NCT03652233, NCT03695510), an EGFR tyrosine kinase inhibitor, downregulates PD-L1 expression via the inhibition of NF-κB.”
BackgroundInfluentialIwata, T., Kondo, Y., Kimura, O. S., Morosawa, T., Fujisaka, Y., Umetsu, T., Kogure, T., Inoue, J., Nakagome, Y., & Shimosegawa, T. (2016) · Scientific Reports · doi:10.1038/srep39296 · Cited by 103
Luheshi, N., Ulrichsen, J. C., Harper, J. A., Mullins, S., Sulikowski, M., Martin, P., Brown, L., Lewis, A. R., Davies, G. C., Morrow, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7610 · Cited by 107
“Alternatively, PD-L1 may have been induced via an IFNγ-independent pathway in this model [36-38].”
BackgroundLai, C., Duan, S., Ye, F., Hou, X., Li, X., Zhao, J., Yu, X., Hu, Z., Tang, Z., Mo, F., et al. (2018) · Theranostics · doi:10.7150/thno.22056 · Cited by 100
“In contrast, decreased numbers of MDSCs and Tregs are associated with a reduction in tumor volume in cancer patients [51].”
Chen, T., Li, Q., Liu, Z., Chen, Y., Feng, F., & Sun, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.044 · Cited by 104
Hypoxia-driven intratumor heterogeneity and immune evasion
Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaïb, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 107
The impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 106
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 111
Self-citationMyeloid‐derived suppressor cells as effectors of immune suppression in cancer
Pyzer, A. R., Cole, L., Rosenblatt, J., & Avigan, D. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30232 · Cited by 98
Liu, Y., Wu, J., Huang, W., Weng, S., Wang, B., Chen, Y., & Wang, H. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02366-0 · Cited by 99
Hypoxia/HIF Modulates Immune Responses
Chen, Y., & Gaber, T. (2021) · Biomedicines · doi:10.3390/biomedicines9030260 · Cited by 120
“Furthermore, the hypoxic microenvironment increases the expression programmed death ligand 1 (PD-L1) on MDSCs, which is when blocked resulting in enhanced MDSC-mediated T cell activation [43] evidencing hypoxia-mediated suppression of anti-tumor T cell effector function supporting tumor development [44–46].”
BackgroundAlleviating hypoxia to improve cancer immunotherapy
Fan, P., Zhang, N., Candi, E., Agostini, M., Piacentini, M., Bernassola, F., Bove, P., Alessandro, M., Giuseppe, N., Valentina, R., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02869-2 · Cited by 105
Regulation of Immune Cell Functions by Metabolic Reprogramming
Kim, J. (2018) · Journal of Immunology Research · doi:10.1155/2018/8605471 · Cited by 108
“Although HIF1α drives the M1 phenotypes in hypoxic conditions, lactate produced by cancer cells, as a by-product of aerobic glycolysis, has an unexpected critical function in HIF1αdependent expression of ARG1 and resultant M2-like activation of TAMs in normoxic conditions [59] (Figure 3).”
InfluentialHypoxia-Induced Resistance to Chemotherapy in Cancer
Minassian, L. M., Cotechini, T., Huitema, E., & Graham, C. H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_9 · Cited by 114
Tumor vessel co-option probed by single-cell analysis
Teuwen, L.-A. M. N., de Rooij, L. P. M. H., Cuypers, A., Rohlenová, K., Dumas, S. J., García‐Caballero, M., Meta, E., Amersfoort, J., Taverna, F., Becker, L. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109253 · Cited by 105
Kim, H., Shim, B. Y., Lee, S., Lee, J. Y., Lee, H. J., & Kim, I.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189795 · Cited by 117
“HIF1α upregulates PD-L1 expression on myeloid-derived suppressor cells (MDSCs) and suppresses overall T-cell activity [85,86].”
BackgroundTurning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 135
Metabolic regulation of immune responses: therapeutic opportunities
Assmann, N., & Finlay, D. K. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83005 · Cited by 97
Chambers, A. M., & Matosevic, S. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00060 · Cited by 95
“Its effects on immune effectors are many: hypoxia has been recognized as an upregulator of the expression of PD-1/PD-L1 on tumor cells via HIF-1α (Noman et al., 2014), and impairing hypoxia sensitizes cancer cells to T cell checkpoint blockade with CTLA-4 and PD-1 (Jayaprakash et al., 2018).”
BackgroundNanomedicine Strategies in Conquering and Utilizing the Cancer Hypoxia Environment
Pan, Y., Liu, L., Mou, X., & Cai, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07763 · Cited by 101
Oncolytic viruses as immunotherapy: progress and remaining challenges
Aurelian, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s63049 · Cited by 100
Zalfa, C., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633205 · Cited by 107
“The red lines indicate the aberrant pathways of myeloid cell differentiation that arise in cancer, in which the TME promotes the development of immunosuppressive populations, including monocytic myeloid-derived suppressor cells (M-MDSCs), polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), inflammatory DCs…”
BackgroundInfluentialZai, W., Kang, L., Dong, T., Wang, H., Yin, L., Gan, S., Lai, W., Ding, Y., Hu, Y., & Wu, J. (2021) · ACS Nano · doi:10.1021/acsnano.1c07621 · Cited by 99
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.